1. Home
  2. INTZ vs TPST Comparison

INTZ vs TPST Comparison

Compare INTZ & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intrusion Inc.

INTZ

Intrusion Inc.

HOLD

Current Price

$0.67

Market Cap

16.4M

ML Signal

HOLD

Logo Tempest Therapeutics Inc.

TPST

Tempest Therapeutics Inc.

HOLD

Current Price

$1.02

Market Cap

15.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INTZ
TPST
Founded
1983
2011
Country
United States
United States
Employees
52
N/A
Industry
Computer Communications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.4M
15.6M
IPO Year
2020
2012

Fundamental Metrics

Financial Performance
Metric
INTZ
TPST
Price
$0.67
$1.02
Analyst Decision
Buy
Strong Buy
Analyst Count
2
1
Target Price
$5.75
$11.00
AVG Volume (30 Days)
207.3K
210.1K
Earning Date
05-12-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
71.78
N/A
EPS
N/A
N/A
Revenue
$7,015,000.00
$295,000.00
Revenue This Year
$25.34
N/A
Revenue Next Year
$14.70
N/A
P/E Ratio
N/A
N/A
Revenue Growth
21.56
N/A
52 Week Low
$0.65
$0.84
52 Week High
$2.27
$12.22

Technical Indicators

Market Signals
Indicator
INTZ
TPST
Relative Strength Index (RSI) 40.02 50.24
Support Level N/A $1.02
Resistance Level $0.88 $1.09
Average True Range (ATR) 0.05 0.08
MACD -0.01 0.04
Stochastic Oscillator 13.84 45.32

Price Performance

Historical Comparison
INTZ
TPST

About INTZ Intrusion Inc.

Intrusion Inc is a cybersecurity company based in Plano, Texas. The company offers its customers access to its exclusive threat intelligence database containing the historical data, known associations, and reputational behavior of Internet Protocol addresses. Its platform combines threat intelligence, malicious traffic identification, and automated threat response, and is designed to help organizations proactively identify and stop malicious activity in their networks. Its solutions include INTRUSION Shield, INTRUSION TraceCop, and INTRUSION Savant. The company operates in single segment.

About TPST Tempest Therapeutics Inc.

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.

Share on Social Networks: